Study: International randomized phase III trial comparing oral sunvozertinib with carboplatin–pemetrexed in untreated advanced nonsquamous NSCLC with EGFR exon 20 insertion mutations.

Key data: N=324. Median PFS 10.3 vs 7.5 months; HR 0.65. 12-month PFS 46.1% vs 26.7%. ORR 58.9% vs 31.1%. Median DOR 11.2 vs 7.1 months. OS immature at 38.9% maturity. Grade ≥3 AEs 75.5% vs 56.7%.

Why it matters: Establishes an oral chemotherapy-free first-line option with superior PFS versus chemotherapy in EGFR exon 20 insertion NSCLC.

Clinical context & caveats: Cross-over was allowed, OS is immature, and CNS activity remains uncertain because baseline brain metastases were few and previously irradiated.

Link

Study: Randomized open-label phase III trial from China evaluating first-line sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab alone in PD-L1 TPS ≥1% advanced NSCLC without targetable genomic alterations.

Key data: N=413. Median PFS not reached vs 5.7 months; HR 0.35. 12-month PFS 62% vs 29%. ORR 70% vs 42%. OS immature; median OS not reached vs 14.5 months; HR 0.55. Grade ≥3 TEAEs 55% vs 31%.

Why it matters: Provides phase III evidence that ADC–IO escalation can substantially improve disease control over pembrolizumab alone in PD-L1-positive advanced NSCLC.

Clinical context & caveats: Conducted entirely in China, OS remains immature, and pembrolizumab monotherapy is a debated comparator for PD-L1 1–49% disease in many settings.

Link

Study: Randomized phase III trial in unresectable stage III NSCLC comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab plus ipilimumab, nivolumab alone, or standard chemoradiotherapy followed by durvalumab.

Key data: N=925. Nivolumab/ipilimumab vs durvalumab: median PFS 16.7 vs 15.6 months; HR 0.95. Median OS 34.6 vs 40.2 months; HR 1.12. Nivolumab alone vs durvalumab: PFS HR 0.84; OS HR 0.97. Treatment-related pneumonitis deaths were more frequent with nivolumab-containing arms than durvalumab.

Why it matters: Confirms that earlier PD-1 exposure and CTLA-4 escalation do not improve on the durvalumab consolidation standard in unresectable stage III NSCLC.

Clinical context & caveats: Numerical PFS signal in PD-L1 ≥50% remains exploratory. The main practical message is caution with concurrent IO–CRT intensification due to pneumonitis risk.

Link

Study: Post-hoc supplementary analysis of the randomized phase III JCOG0802/WJOG4607L trial, evaluating patients with small peripheral clinical stage IA NSCLC and pathologically invasive features.

Key data: N=298 of 1,106 randomized patients. Segmentectomy showed a trend toward better OS than lobectomy, but not significant; HR 0.657, 95% CI 0.401–1.077. RFS was not significantly different; HR 1.265, 95% CI 0.860–1.862. Locoregional relapse was higher after segmentectomy; HR 2.234, 95% CI 1.334–3.741. Death from other causes was lower with segmentectomy; HR 0.359, 95% CI 0.143–0.900.

Why it matters: Supports the long-term value of lung preservation, even in tumors with invasive pathological features.

Clinical context & caveats: Post-hoc analysis. Segmentectomy may preserve future treatment options, but higher locoregional relapse means margins and patient selection remain critical.

Link

Study: Prospective observational J-TAIL-2 study evaluating atezolizumab-containing regimens in real-world Japanese patients with NSCLC and ES-SCLC, including older and trial-ineligible populations.

Key data: N=1,217 treated patients; 814 NSCLC and 403 ES-SCLC. Overall, 53.5% were ≥70 years and 11.8% had ECOG PS ≥2. Median OS was broadly similar in patients ≥70 vs <70 years across regimens, including 18.3 vs 22.3 months with atezo + carboplatin/nab-paclitaxel, 24.0 vs 18.5 months with atezo + platinum/pemetrexed, 17.7 vs 17.0 months with atezo + bevacizumab/carboplatin/paclitaxel, and 16.4 vs 17.9 months with atezo + carboplatin/etoposide. Grade ≥3 AEs and ILD were higher in older patients for some NSCLC regimens.

Why it matters: Supports treatment decisions based on functional reserve rather than chronological age alone.

Clinical context & caveats: Observational design; regimen choice and dose modifications followed clinical practice. G8 and ECOG appeared more informative than age alone.

Link

Study: National nonrandomized open-label phase II trial of oncologist-choice first-line pembrolizumab with or without carboplatin–pemetrexed in patients aged ≥70 years with advanced lung adenocarcinoma.

Key data: N=95 evaluable. Median age 77 years; 11.6% had ECOG PS ≥2. Solicited grade ≥3 AEs within 6 months occurred in 25.6% with pembrolizumab monotherapy and 42.3% with pembrolizumab plus chemotherapy. Median OS was 16.4 months and 29.9 months, respectively. QOL worsened during treatment. Geriatric toxicity risk score was not associated with severe AEs.

Why it matters: Provides prospective safety data for first-line pembrolizumab-based treatment in older adults often underrepresented in registration trials.

Clinical context & caveats: Nonrandomized treatment selection; OS comparisons between arms should not be interpreted causally.

Link

Study: Final OS analysis of the randomized phase III APPLE study evaluating atezolizumab plus carboplatin–pemetrexed with or without bevacizumab in advanced nonsquamous NSCLC.

Key data: N=411 in the ITT population. Median OS 28.0 vs 25.7 months with bevacizumab vs no bevacizumab; HR 0.88, 95% CI 0.70–1.10. In driver-negative disease, OS was 27.6 vs 27.8 months; HR 0.96. In driver-positive disease, OS was 28.0 vs 20.8 months; HR 0.71, 95% CI 0.47–1.08. Safety was unchanged from earlier analysis.

Why it matters: Final OS does not support routine bevacizumab addition to atezolizumab/platinum/pemetrexed in unselected nonsquamous NSCLC.

Clinical context & caveats: The driver-positive subgroup signal is exploratory and should not be overinterpreted.

Link

Study: Post-hoc long-term analysis of a prospective randomized trial comparing passive-scattering proton therapy with IMRT, both with concurrent chemotherapy, in locally advanced NSCLC.

Key data: N=149 analyzed. Grade ≥3 radiation pneumonitis was similar: 10.9% with IMRT vs 10.5% with proton therapy. No differences were seen in local failure or PFS. Radiation-related major adverse cardiac events occurred in 9 IMRT patients and 1 proton patient; cumulative incidence 12.3% vs 1.8%. Median PFS was 10.6 months in both groups. Median OS was 2.5 vs 2.2 years, but treatment modality was not significant in multivariable analysis.

Why it matters: Suggests proton therapy may reduce late cardiac toxicity when cardiac sparing is clinically relevant.

Clinical context & caveats: Passive-scattering proton therapy is older technology; applicability to modern IMPT requires caution.

Link

Study: Nonrandomized phase II trial of functional-lung-avoidance and response-adaptive chemoradiation for unresectable NSCLC using FDG-PET/CT and SPECT/CT.

Key data: N=49. Median follow-up 52.3 months. Median OS 29.1 months; 1-year and 2-year OS 81.6% and 54.2%. Median PFS 12.3 months. Distant metastasis was the dominant failure mode. Baseline FDG-PET total lesion glycolysis was associated with locoregional progression; HR 1.87, p<0.001. Mid-treatment TLG was associated with distant metastasis; HR 1.52, p=0.03.

Why it matters: Supports imaging-guided risk adaptation as a future direction for locally advanced NSCLC radiotherapy.

Clinical context & caveats: Small, single-institution, nonrandomized phase II study. Findings are hypothesis-generating.

Link

Study: Target trial emulation using Veterans Health Administration records comparing morning versus afternoon ICI infusion timing in stage IV NSCLC, with chemotherapy-treated patients as a negative control cohort.

Key data: ICI cohort N=4,688; 1,171 received first three infusions in the morning and 794 in the afternoon. Median OS 10.3 vs 8.1 months. Afternoon dosing was associated with worse OS; HR 1.15, 95% CI 1.04–1.26; p=0.004. In chemotherapy controls, no significant timing effect was seen; HR 1.05, 95% CI 0.98–1.12; p=0.15.

Why it matters: Raises a low-cost, operationally simple hypothesis: ICI timing may matter.

Clinical context & caveats: Observational despite target trial emulation. Confounding by scheduling, frailty, travel burden, and clinic logistics remains possible. Prospective validation is needed before practice change.

Link

EGFR exon 20 insertion NSCLC is moving toward targeted first-line therapy, with sunvozertinib showing clear PFS and response advantages over chemotherapy.

ADC–immunotherapy combinations are becoming one of the most important escalation strategies in advanced NSCLC, but OS maturity and geographic generalizability remain key.

Durvalumab after chemoradiotherapy remains the benchmark in unresectable stage III NSCLC; concurrent PD-1 and CTLA-4 escalation did not improve outcomes.

In early-stage NSCLC, segmentectomy continues to show survival advantages linked to lung preservation, but locoregional relapse risk cannot be ignored.

Older-patient data increasingly support individualized assessment using performance status, geriatric function, comorbidity, and pulmonary reserve rather than age alone.

Radiotherapy studies continue to shift from dose escalation toward risk-adaptation, cardiac sparing, and biomarker-guided selection.

OptiTROP-Lung05 was conducted entirely in China, and OS data remain immature.

WU-KONG28 allowed crossover, making OS interpretation difficult.

CheckMate 73L reinforces pneumonitis risk when immunotherapy is moved into the concurrent chemoradiotherapy phase.

Segmentectomy data are post-hoc and based on pathological features that are not always known preoperatively.

J-TAIL-2 and Alliance A171901 are clinically useful for older patients, but treatment allocation was not randomized.

Proton therapy data used passive-scattering proton therapy, limiting extrapolation to modern IMPT.

Morning versus afternoon ICI timing is provocative but not yet practice-changing.